

Review

Biochemical Functions of Coenzyme Q₁₀

Frederick L. Crane, PhD

Department of Biological Sciences, Purdue University, West Lafayette, Indiana

Key words: energy coupling, antioxidant, transmembrane signaling, gene expression

Coenzyme Q is well defined as a crucial component of the oxidative phosphorylation process in mitochondria which converts the energy in carbohydrates and fatty acids into ATP to drive cellular machinery and synthesis. New roles for coenzyme Q in other cellular functions are only becoming recognized. The new aspects have developed from the recognition that coenzyme Q can undergo oxidation/reduction reactions in other cell membranes such as lysosomes, Golgi or plasma membranes. In mitochondria and lysosomes, coenzyme Q undergoes reduction/oxidation cycles during which it transfers protons across the membrane to form a proton gradient. The presence of high concentrations of quinol in all membranes provides a basis for antioxidant action either by direct reaction with radicals or by regeneration of tocopherol and ascorbate. Evidence for a function in redox control of cell signaling and gene expression is developing from studies on coenzyme Q stimulation of cell growth, inhibition of apoptosis, control of thiol groups, formation of hydrogen peroxide and control of membrane channels. Deficiency of coenzyme Q has been described based on failure of biosynthesis caused by gene mutation, inhibition of biosynthesis by HMG coA reductase inhibitors (statins) or for unknown reasons in ageing and cancer. Correction of deficiency requires supplementation with higher levels of coenzyme Q than are available in the diet.

Key teaching points:

- Coenzyme Q is needed for energy conversion.
- Coenzyme Q is an essential antioxidant.
- Coenzyme Q regenerates other antioxidants.
- Coenzyme Q stimulates cell growth and inhibits cell death.
- Decreased biosynthesis may cause deficiency.

INTRODUCTION

The point to emphasize is that coenzyme Q has several biochemical functions [1]. The well recognized functions are in mitochondrial energy coupling and its action as a primary regenerating antioxidant. Less well established functions include oxidant action in the generation of signals and control of cellular redox state. By participation in transmembrane electron transport coenzyme Q can carry reducing equivalents to the inside of vesicles or to the outside of cells. There is also evidence for a role in proton gradient formation in endomembranes and at the plasma membrane. In addition, there is evidence that coenzyme Q can take part in control of membrane structure and phospholipid status [2,3].

Coenzyme Q is 2,3-dimethoxy,5-methyl, 6-polyisoprene parabenzoquinone. The coenzyme Q₁₀ found in humans has a polyisoprene chain containing 10 isoprene units (5 carbons each) or a total of 50 carbons. The all *trans* polyisoprene ensures an affinity for the interior of cell membranes. The two methoxy groups contribute to the specificity in enzyme action as may the methyl group. The fully substituted quinone ring does not allow addition reactions with thiol groups in the cell such as glutathione, thioredoxin or thioctic acid. The functional group is the quinone ring. By reduction of the quinone to quinol a carrier of protons and electrons is produced [4].

Coenzyme Q is distributed in all membranes throughout the cell [5]. In mitochondria there are well defined protein binding sites on the enzymes involved in coenzyme Q oxidation reduction

Presented in part at the 41st Annual Meeting, American College of Nutrition, Las Vegas, Nevada, October 12, 2000.

Address correspondence to: Frederick L. Crane, Ph D, Department of Biological Sciences, Purdue University, West Lafayette, Indiana.

Journal of the American College of Nutrition, Vol. 20, No. 6, 591–598 (2001)

Published by the American College of Nutrition

[6]. Enzymes in other membranes can be expected to have specific coenzyme Q binding sites, but these have not been defined. In addition there is coenzyme Q floating in the phospholipid bilayer of the membranes. The free form may float with the all *trans* polyisoprene chain extended in a long linear structure with the methyl groups intercalated in the fatty acid chains of the lipid. There is also evidence that in some cases the polyisoprenoid chain may be folded into a shorter, thicker structure. It is thought that the isoprenoid chain may help to stabilize the lipid bilayer [2]. The quinone head group can be either the oxidized (quinone) or reduced (quinol) form. In most membranes enzymes have been defined which can reduce the quinone and oxidize the quinol. The percent in quinol form in various membranes and serum ranges from 30% to 90%, depending on the metabolic state of the cell [7]. The quinol (hydroquinone) is more hydrophilic, so the head group can lie closer to the surface of the membrane. The change of position with oxidation/reduction may modify structural or enzymatic properties in the membrane. For example, the redox state may control activity of phospholipases in the membrane [3].

Genetic mutation, ageing, cancer and statin type drugs can cause a decrease of coenzyme Q in serum or tissue (Table 1). The precise membranes in all cells which have less are not known, but deficiency can be observed in mitochondria of some cells but not in others. The amount of coenzyme Q in the diet is not sufficient to increase serum coenzyme Q significantly. Significant increase of coenzyme Q in serum requires supplementation with about 100 mg/day.

ENERGY COUPLING

Coenzyme Q is an essential part of the cellular machinery used to produce ATP which provides the energy for muscle

Table 1. Coenzyme Q Deficiency in Humans

Basis	Tissue Analysis	% Decrease from Control	Ref
Genetic	Lymphocytes	—	[49]
Age***	Myocardium	72%	[50]
Age*	Heart	58%	[63]
Age*	Pancreas	83%	[63]
Age*	Adrenal	50%	[63]
Age*	Liver	17%	[63]
Age*	Kidney	45%	[63]
Age**	Skin epidermis	75%	[21]
Genetic	Skin fibroblasts	90%	[49]
Pravastatin ⁰	Serum	20%	[64]
Lovastatin ⁰	Serum	29%	[64]
Simvastatin ⁰	Serum	26%	[65]
Cancer (pancreas)	Serum	30%	[66]
Diabetic (NIDDM)	Serum	65%	[67]

* Change from age 19–21 to age 77–81.

** Change from age 30 to age 80.

*** Change from avg. age 58 ± 1.7 to 76 ± 6.8.

⁰ HMG CoA reductase inhibitors of isoprene synthesis.

contraction and other vital cellular functions. The major part of ATP production occurs in the inner membrane of mitochondria, where coenzyme Q is found. The coenzyme Q has a unique function since it transfers electrons from the primary substrates to the oxidase system at the same time that it transfers protons to the outside of the mitochondrial membrane. This transfer results in a proton gradient across the membrane. As the protons return to the interior through the enzymatic machinery for making ATP, they drive the formation of ATP. The coenzyme Q is bound to the oriented enzymatic protein complexes. It is oxidized and releases protons to the outside and picks up electrons and protons on the inside of the mitochondrial membrane [8, 9].

There are two protein complexes in the membrane where electrons and protons are transferred through coenzyme Q. The first is the primary reductase where coenzyme Q is reduced by NADH (complex I). During the reduction process four protons are transported across the membrane for every coenzyme Q reduced [8 (Fig. 1)]. The details of this process are still unclear, but it has been proposed that coenzyme Q is reduced and reoxidized in the complex twice before electrons are transferred to a second loosely bound coenzyme Q to form quinol which can travel through the lipid in the membrane to a second complex where the quinol is oxidized again (complex III) with transfer of protons across the membrane [9 (Fig. 2)]. The details of quinol binding and oxidation at the binding site in this complex are well known. As in complex I, there is a cyclic oxidation-reduction-reoxidation with the oxidation and proton release step always on the outside so that protons are released in the right direction. Again the oxidation-reduction cycle allows for four protons to cross the membrane for each quinol oxidation cycle. The quinone cycle thus doubles the efficiency of the coenzyme Q in building up the proton charge across the membrane which allows twice as much ATP production than a simple one step oxidation of quinol. After the cycle is completed the oxidized quinone migrates through the membrane to be rereduced at complex I.

A simpler form of energy conversion based on coenzyme Q reduction-oxidation is found in lysosomes [10]. In this case the




Fig. 1. Reductive Q cycle. Scheme proposed [8] for reduction and proton transfer through the tightly bound coenzyme Q in complex I. Partial oxidation of quinol allows recycling of the quinone to carry more protons across the membrane than electrons transferred to the loosely bound coenzyme Q which travels in the lipid bilayer to be oxidized in complex III.




Fig. 2. Oxidative Q cycle. Scheme proposed [9] for partial oxidation of the quinol to provide electrons from the semiquinone for rereduction of quinone to quinol with uptake of protons for transfer across the membrane.

quinol transfers a proton across the lysosomal membrane to acidify the inside which involves energy input to work against a proton gradient. No ATP can be formed since the lysosomal membrane does not have a proton driven ATP synthetase. The acidification of the lysosome activates hydrolytic enzymes for digestion of cellular debris. In other words, coenzyme Q energizes cell house cleaning. The details of the enzymes and possible Q binding sites in the lysosomal membrane are not known. The enzyme complex in the membrane involves reduction of coenzyme Q by NADH in the cytoplasm and reoxidation of the quinol by oxygen.

Another site where coenzyme Q may be involved in vesicle acidification is in pinocytotic endosomes which engulf iron and transferrin bound to transferrin receptors and carry it into the cell. There is a redox system in the membranes of these vesicles which can acidify their interior [11]. Reduction of transferrin-bound iron in an acid environment releases the iron for uptake into the cytoplasm. The possible role of coenzyme Q in iron reduction and proton transfer in these membranes has not been established.

Another role for coenzyme Q in proton movement is indicated at the plasma membrane. In this situation coenzyme Q is involved in activation of Na⁺/H⁺ exchange across the membrane carried out by the Na⁺/H⁺ antiport. The energy for this process is based on a high concentration of Na⁺ outside the cell which exchanges for protons in the cell. The Na⁺ is then pumped out of the cell by the Na⁺/K⁺ ATPase which obtains energy from ATP. During this ATP action excess Na⁺ is released so the cell develops an inside negative membrane potential which is important for many cellular functions and transport action [12]. Coenzyme Q is involved in a plasma membrane electron transport system by which NADH in the cytoplasm transfers electrons through coenzyme Q to electron acceptors such as iron or oxygen outside the cell. When this

system is activated, the proton release through the H⁺/Na⁺ antiport is greatly increased. When the system is inhibited by inhibitory coenzyme Q analogs, the antiport is inhibited. As a result of activation of the antiport, the interior of the cell becomes more alkaline. The mechanism by which the coenzyme Q dependent electron transport activates the antiport is not known [13].

If the Na⁺/H⁺ antiport is inhibited by amiloride, the transplasma membrane electron transport is accompanied by a slow release of protons equivalent to two protons released per quinol oxidized. This proton release indicates that the reduction oxidation of the coenzyme Q in the membrane is organized as in the lysosomes. In contrast, the proton release by activation of the antiport is more than ten times greater than the electron transport driven proton transfer.

ANTIOXIDANT FUNCTIONS

Coenzyme Q is well located in membranes in close proximity to the unsaturated lipid chains to act as a primary scavenger of free radicals. The amount of CoQ in many membranes is from three to 30 times the tocopherol content [14] (also see Table 2)]. Since much of the coenzyme Q in cell membranes is in the quinol form [15], it can be a very effective antioxidant [16]. Even more important is the presence of enzymes in all membranes which can reduce any coenzyme Q quinone radical generated by reaction with lipid or oxygen radicals. At least three enzymes are known which can keep the coenzyme Q reduced in plasma and endomembranes [1]. These enzymes are (1) NADH cytochrome b5 reductase [17], (2) NADH/NADPH oxidoreductase (DT diaphorase [17]), (3) NADPH coenzyme Q reductase [18]. In mitochondria the NADH and succinate dehydrogenases can keep coenzyme Q partly reduced. Reductases 1 and 3 in endomembranes can be especially important by one electron transfer to rereduce any semiquinone generated by reaction of quinol with a radical. The DT diaphorase is unique since it can directly reduce, by 2 electron transfer, any quinone formed without intermediate formation of the semiquinone. Under conditions of oxidative stress induced by nutritional lack of selenium and α-tocopherol, the coenzyme Q in membranes is greatly increased. The amount of DT diaphorase attached to

Table 2. Coenzyme Q in Cell Membranes and Relation to α-Tocopherol

Rat Liver Membranes	CoQ/αtoc mol/mol	CoQ μg/mg protein
Mitochondria (cristae)	35	1.9
Plasma membrane	21	0.7
Peroxisomes	3	0.3
Lysosomes	3	1.9
Golgi membranes	1	2.6
Endoplasmic reticulum	1	0.2

Data based on [5,14].

membranes where it can reduce coenzyme Q is also remarkably increased [19]. Similar decrease in α -tocopherol induced by peroxisomal proliferator is accompanied by a large increase in coenzyme Q [14].

A direct demonstration of the effectiveness of coenzyme Q as an antioxidant can be shown with coenzyme Q deficient yeast. A yeast mutant deficient in coenzyme Q synthesis shows more lipid peroxide formation than normal yeast [20]. Another direct demonstration of elimination of free radicals is shown by coenzyme Q treatment of skin in older persons. Luminescence from free radicals is eliminated when a skin cream containing coenzyme Q is applied [21].

In addition to direct antioxidant radical scavenging, the quinol can rescue tocopheryl radicals produced by reaction with lipid or oxygen radicals by direct reduction back to tocopherol [22]. Without coenzyme Q in a membrane, regeneration of tocopherol is very slow. The regeneration of tocopherol can also be observed in low density lipoprotein where a small amount of coenzyme Q protects a larger amount of tocopherol. This function is presumably favored by the high percent of quinol present in blood [23, 24].

There is some evidence that the coenzyme Q dependent electron transport across the plasma membrane can be used to regenerate ascorbate outside the cell from ascorbate radical (monodehydroascorbate [25]). Ascorbate inside the cell can be regenerated by a glutathione based system. Regeneration outside requires electron transfer through the plasma membrane, some of which depends on the presence of coenzyme Q in the membrane.

CELL SIGNALING AND GENE EXPRESSION

Coenzyme Q can participate in several aspects of oxidation/reduction control of signal origin and transmission in cells. The autooxidation of the semiquinone formed in various membranes during electron transport activity can be a primary basis for generation of H₂O₂ [1,26]. The H₂O₂ in turn activates transcription factors such as NF κ B to induce gene expression [27]. Peroxide can also be involved in calcium signaling in cardiac muscle [28]. It is also possible that reactive oxygen species generation may lead to suppression of other genes. The quinone can also participate in oxidation of thiol groups on growth factor receptors or membrane ion channels. An example is ryanodine receptor controlled Ca⁺⁺ release which may also be related to oxygen sensing [29,30]. On the other hand, reduction of disulfide bonds by the quinol would require energy driven reverse electron transport since the redox potential of coenzyme Q is higher (+100 mV) than the thiol-disulfide couple (-320 mV). A proton gradient driven electron transport as seen in reduction of NAD by succinate in mitochondria would drive this disulfide reduction by the quinol. Control of the redox state of protein disulfide isomerase at the cell surface

by the quinol oxidase or the quinone reductase has been discussed [31].

Formation of the coenzyme Q semiquinone in complex III of mitochondria has long been cited as a primary source of superoxide and subsequently hydrogen peroxide in cells [32]. This source is controlled by the redox state or degree of energy coupling in the mitochondria [26]. Similar control applies to H₂O₂ production at the succinate dehydrogenase (complex II) or NADH dehydrogenase (complex I) sites for reduction/oxidation of coenzyme Q [26 (Fig. 3)]. It is expected that binding of the semiquinone in these complexes would decrease autooxidation, but any condition which disturbs the equilibrium between quinone and binding protein to allow quinone exposure may encourage peroxide production [33].

Since coenzyme Q is not restricted to mitochondria and the coenzyme Q in other membranes undergoes oxidoreduction [10,34,35], there is probably potential for peroxide generation in all membranes. Certainly lysosome, Golgi and plasma membranes are candidates. Plasma membranes do generate peroxide during oxidation of NADH [36].

Although there are enzymes which can reduce coenzyme Q in all endomembranes and in plasma membrane, the presence of binding sites which can protect the semiquinone from autooxidation and prevent subsequent peroxide production are unknown. Furthermore, enzymes for oxidation of quinol in plasma membrane have been identified. A cell surface NADH oxidase and a transplasma membrane NADH oxidase have been observed [37]. The surface oxidase also acts as a coenzyme Q quinol oxidase [38] and shows evidence for superoxide generation [37]. The quinol oxidase portion of the transmembrane oxidase has not been isolated but it appears to require non-heme iron since it is reversibly inhibited by impermeable iron chelators [39]. The transmembrane NADH oxidase requires coenzyme Q [35]. A second transplasma membrane NAD(P)H oxidase has been defined which is homologous with




Fig. 3. Sites for semiquinone formation in the redox complexes of mitochondria. Complex I, II and III generate semiquinone which takes part in normal electron transfer. If semiquinone accumulates because of inhibitors, excess substrate or excess proton accumulation, the semiquinone can be autooxidized to produce superoxide [26]. Semiquinone formation in fatty acid oxidation (FA) would probably be associated with the electron transfer flavoprotein (ETF) coenzyme Q oxidoreductase ETFQR [70]. Glycerol-3-phosphate dehydrogenase also reacts with coenzyme Q (not shown [71]).

the superoxide generating NADPH oxidase found in neutrophil plasma membrane [40, 41]. This oxidase uses cytochrome b558 to produce superoxide and is characteristic of transformed and tumor cells. The coenzyme Q dependent transmembrane enzyme has been defined in rat liver and heart cells and appears to be a normal component in all animal cells [13]. The extent to which it can be activated to produce superoxide has not been defined. Possible evidence that superoxide production induced by phorbol myristate acetate depends on coenzyme Q is suggested by retinoic acid inhibition in Balb 3T3 cells [42]. Retinoic acid does not inhibit transformed Balb 3T3 cells. Loss of retinoic acid response suggests that the b558 oxidase predominates over the coenzyme Q system in some transformed cells [1].

At this point we do not know which plasma membrane electron transport system is responsible for superoxide and peroxide formation at the cell surface of different types of cells (Fig. 4). The inhibition of transplasma membrane electron transport in transformed cells by antitumor drugs but not in untransformed cells suggests that the b₅₅₈ (Mox 1) enzyme is activated in these cells as it is in the ras mutant cells [1,43,44]. On the other hand retinoic acid appears to be a specific inhibitor for the system in nontransformed cells which presumably is the coenzyme Q dependent system [44] since the transmembrane enzyme in normal liver cells is largely dependent on coenzyme Q [35].

The effect of the plasma membrane electron transport on cell proliferation is probably not exclusively related to generation of H₂O₂. This is seen in the effect of ferricyanide as an external electron acceptor on the expression of c-myc and c-fos genes in C3H 10T1/2 cells [45]. Since ferricyanide will destroy any peroxide produced at the cell surface, its growth effect may be based on alteration of the cytosolic redox state by oxidation of NADH [46]. The basis for inhibition of apoptosis by coenzyme Q remains to be established. The effect may be based on redox control or on membrane structure control and modification of phospholipid as in the inhibition of ceramide formation [17, 47]. The role of coenzyme Q in signal transduction, gene expression and membrane channels is therefore a new area in need of further study. There is ample evidence that it is involved in significant control functions.

DEFICIENCY

In normal healthy individuals coenzyme Q is synthesized in all cells from tyrosine (or phenylalanine) and mevalonate [48]. Only four cases are reported with genetic based failure of synthesis [49]. Low levels of coenzyme Q are found in disease or ageing [21,50,51,52]. It is not clear how the distribution of coenzyme Q in tissue is controlled. In tissues with unimpaired synthetic capacity, it appears that coenzyme Q in each membrane reaches a saturation level [53]. Thus supplementation with coenzyme Q does not increase tissue levels above normal (except in liver and spleen). This is especially true in young,




Fig. 4. Plasma membrane redox functions. Two types of transplasma membrane electron transfer are known. One type uses coenzyme Q as a transmembrane electron carrier [72]; the other uses a low redox potential cytochrome b558 complex. This enzyme is analogous to the peroxide generating GP91 phox of neutrophils (n [40, 41]) and may be characteristic of transformed cells (t [73]). In addition, cytosolic ascorbate can reduce external semidehydroascorbate through a cytochrome b561 in some cells. Three different NAD(P)H dehydrogenases (reductases) on the plasma membrane can reduce coenzyme Q [17, 18]. Two different enzymes are indicated for oxidation of the Q quinol. One is a coenzyme Q oxidase at the outer surface which can oxidize quinol at the outer surface with production of superoxide [37]. The other is an external site sensitive to iron chelators [39]. It can be expected that autooxidation of the iron in neutral pH will produce superoxide [74]. It is not known which system is responsible for diferric transferrin reduction at the cell surface [75]. The recycling of the iron on the transferrin through reoxidation by oxygen could also produce superoxide since diferric transferrin stimulates NADH oxidation by plasma membrane. The peroxide produced by either of these oxidase systems can then feed back into the cell to activate gene transcription [27], SH-S-S controlled calcium channels [28, 76] or inhibit phosphotyrosine phosphatase [77]. The mechanism of control of the Na⁺/H⁺ antiport is not known. Tf is transferrin. The mechanism for redox control of the Na⁺/H⁺ antiport [12] or Ca⁺⁺ activated K⁺ channels is not known [78]. Gene transcription regulated by the hemopexin system is controlled by surface copper reduction dependent on coenzyme Q [79,80].

healthy animals. In older animals with decreased coenzyme Q, in some tissue, supplemental coenzyme Q can restore normal levels [50,53,54]. In addition to decrease in biosynthesis, other factors may affect levels or function of coenzyme Q. These include increase in degradation [55] or changes in membrane lipids to impede quinone movement [56]. Changes of coenzyme Q in different tissues and cell membranes with ageing seem to vary. For example, ageing rats decrease coenzyme Q

Table 3. Coenzyme Q in the Diet

Food		CoQ ₁₀ Content μg/g	Daily Portion g/day	CoQ ₁₀ Intake mg/day
Meat	Pork heart	203	120	24
	Chicken leg	17	120	2.0
	Beef heart	41	120	4.8
	Beef liver	19	120	2.3
	Lamb leg	2.9	120	3.5
Fish	Frog leg	5	120	0.6
	Herring	27	26	0.7
	Trout	11	100	1.1
Vegetable	Cauliflower	0.6	200	0.12
	Spinach	2.3	200	0.46
	Potato	.24	200	0.05
Fruit	Orange	2.2	200	0.44

Data based on [68,69].

selectively in skeletal muscle mitochondria [57] but increase coenzyme Q in mitochondria from brain [58]. Changes in other membranes with ageing need to be determined in relation to loss of function or antioxidant capability.

Nutritional replenishment of coenzyme Q requires a higher level than is available in most food (Table 3). The normal level in blood is around 1 μg/mL [51,59,60]. To increase the concentration significantly requires at least 100 mg/day which can increase the level in blood to around 2 μg/mL or more. An increase to 2 μg/mL in blood can be therapeutic for various conditions [61]; this may indicate that a high blood level is needed to get coenzyme Q into deficient tissues. Even with large amounts of heart or herring in the diet, it would be difficult to supply 100 mg/day.

CONCLUSION

The important point to consider is that coenzyme Q is not just an agent for energy transduction in mitochondria. It is a functional element in all cell membranes. Part of this wider function is based on its antioxidant action with unique capacity for regeneration of redox capacity and a unique location deep in membrane structure. In addition there is growing evidence for a role in control of cell functions and growth. Gene activation or suppression may be based on peroxide production or control of thiol redox state. Other signal functions may involve control of membrane channels, structure and lipid stability.

Biosynthesis in mitochondria and endoplasmic reticulum provides sufficient coenzyme Q for normal individuals. It is not clear if two separate sites of synthesis are involved and how they are controlled [5,62]. Evidence for deficiency is based on genetic failure, age, disease or drugs which inhibit synthesis.

REFERENCES

1. Crane FL: New functions for coenzyme Q. *Protoplasma*, 213:127–133, 2000.

2. Lenaz G, Faro R, DeBernardo S, Jarreta D, Costa, A, Genova ML, Parenti Castelli G: Location and mobility of coenzyme Q in lipid bilayers and membranes. *Biofactors* 9:87–94, 1999.

3. Lopez-Lluch G, Barroso MP, Martin SF, Fernandez-Ayala DJM, Viialba JM, Navas P: Role of plasma membrane coenzyme Q on the regulation of apoptosis. *Biofactors* 9:171–177, 1999.

4. Lenaz G (ed): “Coenzyme Q.” Chichester: Wiley, 1985.

5. Kalen A, Norling B, Appelkvist EL, Dallner G: Ubiquinone biosynthesis by the microsomal fraction of rat liver. *Biochim Biophys Acta* 926:70–78, 1987.

6. Cramer WA, Soriano GM: Energy transduction function of the quinone reactions in cytochrome bc complexes. *Biofactors* 9:81–86, 1999.

7. Yamamoto Y, Yamashita S: Plasma ratio of ubiquinol and ubiquinone as a marker of oxidative stress. *Mol Aspect Med* 18(S):79–84, 1997.

8. Brandt U: Proton translocation in the respiratory chain involving ubiquinone—a hypothetical semiquinone switch mechanism for complex I. *Biofactors* 9:95–102, 1999.

9. Yu CA, Zhang K-P, Deng H, Xia D, Klm H, Deisenhofer J, Yu L: Structure and reaction mechanisms of the multifunctional mitochondrial cytochrome bc₁ complex. *Biofactors* 9:103–110, 1999.

10. Gille L, Nohl H.: The existence of a lysosomal redox chain and the role of ubiquinone. *Arch Biochem Biophys* 375:347–354, 2000.

11. Basset P: Iron supply and cell growth control. In Crane FL, Morré DJ, Löw H (eds): “Oxidoreduction at the Plasma Membrane 1.” Boca Raton: CRC Press, pp 186–2204, 1990.

12. Crane FL, Sun IL, Crowe, RA, Löw H: Oxidase control of plasma membrane proton transport. In Bittar EE, Bittar N (eds): “Principles of Medical Biology: 4, Cell Chemistry and Physiology, Part III.” Greenwich, CT: JAI Press, pp 169–186, 1996.

13. Crane FL, Sun IL, Crowe R, Löw H: Electron and proton transport across the plasma membrane. *J Bioenerg Biomemb* 23:773–803, 1991.

14. Turunen M, Sindelar P, Dallner G: Induction of endogenous coenzyme Q biosynthesis by administration of peroxisomal inducers. *Biofactors* 9:131–140, 1999.

15. Takahashi T, Okamoto T, Mori K, Sayo H, Kishi T: Distribution of ubiquinone and ubiquinol homologues in rat tissues and subcellular fraction. *Lipids* 28:803–809, 1993.

16. Quinn PJ, Fabisiak JP, Kagan VE: Expansion of the antioxidant function of vitamin E by coenzyme Q. *Biofactors* 9:149–154, 1999.

17. Villalba JM, Navas P: Plasma membrane redox system in the control of stress induced apoptosis. *Antioxid Redox Signal* 2:213–230, 2000.

18. Takahashi T, Okamoto T, Kishi T: Characterization of NADPH dependent ubiquinone reductase activity in rat liver cytosol. *J Biochem* 119:256–263, 1996.

19. Navarro F, Arroyo A, Martin SF, Bello RI, de Cabo R, Burgess JR, Navas P, Villalba JM: Protective role of ubiquinone in vitamin E and selenium deficient plasma membranes. *Biofactors* 9:163–170, 1999.

20. Poon WW, Do TQ, Marbois BN, Clarke CF: Sensitivity to treatment with polyunsaturated fatty acids is a general characteristic of the ubiquinone-deficient yeast coq mutants. *Mol Aspect Med* 18(S):121–128, 1997.

21. Hoppe U, Bergemann J, Diembeck W, Ennen J, Gohla S, Harris I,

- Jacob J, Kielholz J, Mei W, Pollet D, Schachtschabel D, Suermann G, Schreiner V, Stab F, Steckel F: Coenzyme Q, a cutaneous antioxidant and energizer. *Biofactors* 9:371–378, 1999.
22. Arroyo A, Kagan VE, Tyurin VA, Burgess JR, de Cabo R, Navas P, Villalba JM: NADH and NADPH dependent reduction of coenzyme Q at the plasma membrane. *Antioxid Redox Signal* 2:251–262, 2000.
 23. Thomas SR, Witting PK, Stocker R: A role for reduced coenzyme Q in atherosclerosis. *Biofactors* 9:207–224, 1999.
 24. Schneider D, Elstner EF: Coenzyme Q₁₀, vitamin E and dihydrothiolic acid cooperatively prevent diene conjugation in isolated low density lipoprotein. *Antiox Redox Signal* 2:327–333, 2000.
 25. Villalba JM, Crane FL, Navas P: Antioxidative role of ubiquinone in the animal plasma membrane. In Asard H, Berczi A, Caubergs RJ (eds): “Plasma Membrane Redox Systems and their Role in Biological Stress and Disease.” Dordrecht: Kluwer, pp 247–266, 1998.
 26. McLennan H, Degli Esposti M: The contribution of mitochondrial respiratory complexes to the production of reactive oxygen species. *J Bioenerg Biomemb* 32:153–162, 2000.
 27. Kaltschmidt B, Sparna T, Kaltschmidt C: Activation of NFκB by reactive oxygen intermediates in the nervous system. *Antioxid Redox Signal* 1:129–144, 1999.
 28. Morad M, Suzuki YJ: Redox regulation of cardiac muscle calcium signaling. *Antioxid Redox Signal* 2:65–71, 2000.
 29. Eu JP, Surr J, Xu L, Stamler JS, Meissner G: The skeletal muscle calcium release channel: coupled O₂ sensor and NO signaling functions. *Cell* 102:499–509, 2000.
 30. Pessah IN, Feng W: Functional role of hyperreactive sulfhydryl moieties within the ryanodine receptor complex. *Antiox Redox Signal* 2:17–25, 2000.
 31. Ryser HJ-P, Mandel R, Gallina A, Rivera A: Plasma membrane disulfide isomerase. In Asard H, Berczi A, Caubergs RJ (eds): “Plasma Membrane Redox Systems and their Role in Biological Stress and Disease,” Dordrecht: Kluwer, pp 279–308, 1998
 32. Hansford RG, Hogue BA, Mildaziene V: Dependence of H₂O₂ formation by rat heart mitochondria on substrate availability and donor age. *J Bioenerg Biomemb* 29:89–95, 1997.
 33. Nohl H, Gille L, Schönheit K, Lin Y: Conditions allowing redox cycling ubiquinone in mitochondria to establish a direct couple with molecular oxygen. *Free Radical Bio Med* 20:207–213, 1996.
 34. Crane FL, Sun IL, Barr R, Morr  DJ: Coenzyme Q in Golgi apparatus membrane redox activity and proton uptake. In Folkers K, Yamamura Y (eds): “Biomedical and Clinical Aspects of Coenzyme Q,” vol 4. Amsterdam: Elsevier, pp 77–86, 1984.
 35. Sun IL, Sun EE, Crane FL, Morr  DJ, Lindgren A, L w H: A requirement for coenzyme Q in plasma membrane electron transport. *Proc Nat Acad Sci US* 89:11126–11130, 1992.
 36. Ramasarma T, Swaroop A, MacKellar W, Crane FL: Generation of hydrogen peroxide on oxidation of NADH by hepatic plasma membranes. *J Bioenerg Biomemb* 13:241–253, 1981.
 37. Berridge MV, Tan S: High capacity redox control at the plasma membrane of mammalian cells: Transmembrane, cell surface and serum NADH oxidases. *Antioxid Redox Signal* 2:231–242, 2000.
 38. Kishi, T, Morr  DM, Morr  DJ: The plasma membrane NADH oxidase of HeLa cells has hydroquinone oxidase activity. *Biochem Biophys Acta* 1412:66–77, 1999.
 39. Alcaín FJ, L w H, Crane FL: Iron at the cell surface controls both DNA synthesis and plasma membrane redox system. *Protoplasma* 184:233–237, 1995.
 40. Meier B, Jesaitis AJ, Emmendorffer A, Roeslee J, Quinn MT: The cytochrome b-558 molecules involved in the fibroblast and polymorphonuclear leucocyte superoxide generating NADPH oxidase systems are structurally and genetically distinct. *Biochem J* 289: 481–486, 1993.
 41. Suh Y-A, Arnold R, Lassegne B, Shi J, Xu X, Sorensen D, Chung AB, Griendling KK, Lambeth JD: Cell transformation by the superoxide generating oxidase Mox-1. *Nature* 401:79–82, 1999.
 42. Crane FL, Sun IL, Sun EE, Crowe RA: Plasma membrane redox and regulation of cell growth. *Protoplasma* 184:3–7, 1995.
 43. Sun IL, Crane FL, Chou JY: Modification of transmembrane electron transport activity in plasma membrane of SV 40 transformed pineal cells. *Biochim Biophys Acta* 886:327–336 1986.
 44. Sun IL, Crane FL: Interactions of antitumor drugs with plasma membranes. In Crane FL, Morr  DJ, L w H (eds): “Oxidoreduction at the Plasma Membrane.” Boca Raton: CRC Press, pp 257–280, 1990.
 45. Wenner CE, Cutry AF: The stimulation of cell growth by extracellular oxidants. In Crane FL, Morr  DJ, L w H (eds): “Oxidoreduction at the Plasma Membrane,” Boca Raton: CRC Press, pp 131–139, 1990.
 46. Navas P, Sun IL, Morr  DJ, Crane FL: Decrease of NADH in HeLa cells in presence of transferrin or ferricyanide. *Biochem Biophys Res Commun* 133:110–115, 1986.
 47. Fernandez-Ayala DJM, Martin SF, Barroso MP, Gomez-Diaz C, Villalba JM, Rodriguez-Aguilera JC, Lopez-Lluch G, Navas P: Coenzyme Q protects cells against serum withdrawal-induced apoptosis by inhibition of ceramide release and caspase 3 activation. *Antioxid Redox Signal* 2:263–276, 2000.
 48. Schultz JR, Clarke CF: Functional roles of ubiquinone. In Cardenas E, Packer L (eds): “Mitochondria, Oxidants and Ageing.” New York: M Dekker, pp 95–118, 1999.
 49. Rotig A, Appelkvist EL, Geromel V, Chretien D, Kadhom N, Ederly P, Lebidean M, Dallner G, Munnich A, Ernster L, Rustin P: Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q₁₀ deficiency. *Lancet* 356:391–395, 2000.
 50. Rosenfeldt FL, Pepe S, Ou R, Mariani JA, Rowland MA, Nagley P, Linnane AW: Coenzyme Q₁₀ improves the tolerance of the senescent myocardium to aerobic and ischemic stress. *Biofactors* 9:291–300, 1999.
 51. Willis R, Anthony M, Sun L, House Y, Qiao G: Clinical implications of the correlation between coenzyme Q₁₀ and vitamin B6 status. *Biofactors* 9:359–363, 1999.
 52. Hodges S, Hertz N, Lockwood K, Lister R: CoQ₁₀: could it have a role in cancer management. *Biofactors* 9:365–370, 1999.
 53. Beal MF: Coenzyme Q administration and its potential for treatment of neurodegenerative diseases. *Biofactors* 9:261–266, 1999.
 54. Reahal S, Wringleworth J: Tissue concentration of coenzyme Q₁₀ in rat following its oral and intraperitoneal administration. *Brug Metabol Dispos* 20:423–427, 1992.
 55. Nakamura T, Ohno T, Hamamura K, Sato T: Metabolism of coenzyme Q₁₀: biliary and urinary excretion study in guinea pigs. *Biofactors* 9:111–120, 1999.
 56. Kagan VE, Nohl H, Quinn JP: Coenzyme Q: its role in scavenging and generation of radicals in membranes. In Cardenas E, Packer

- LM (eds): "Handbook of Antioxidants." New York: M Dekker, pp 157–201, 1996.
57. Lass A, Kwong L., Sohal RS: Mitochondrial coenzyme Q content and ageing. *Biofactors* 9:199–205, 1999.
58. Battino M, Svegliali Baroni S, Littarru GP, Bompadre S, Leone L, Gorini A, Villa RF: Coenzyme Q homologs and vitamin E in synaptic and non-synaptic occipital cerebral cortex mitochondria in the ageing rat. *Mol Aspects Med* 18(S):279–282, 1997.
59. Munkholm H, Hansen HHT, Rasmussen K: Coenzyme Q₁₀ treatment in serious heart failure. *Biofactors* 9:285–289, 1999.
60. Eriksson JG, Forsen TJ, Mortensen SA, Rohde M: The effect of coenzyme Q₁₀ administration on metabolic control in patients with type 2 diabetes mellitus. *Biofactors* 9:315–318, 1999.
61. Langsjoen PH, Langsjoen AM: Overview of the use of CoQ₁₀ in cardiovascular disease. *Biofactors* 9:273–284, 1999.
62. Poon WW, Barkovich RJ, Hsu AY, Frankel A, Lee PT, Shepherd JN, Myles DC, Clark CF: Yeast and rat Coq 3 and E. coli Ubi G polypeptide both catalyse O-methyltransferase steps in coenzyme Q biosynthesis. *J Biol Chem* 274:21665–21672, 1999.
63. Kalen A, Appelkvist E-L, Dallner G: Age related changes in the lipid composition of rat and human tissues. *Lipids* 24:579–584, 1989.
64. Mortensen SA, Leth A, Agner E, Rohde M: Dose related decrease of serum CoQ₁₀ during treatment with HMG-CoA reductase inhibitors. *Mol Aspect Med* 18(S):137–144, 1997.
65. Bargossi AM, Grossi G, Fiorelia PL, Gaddi A, Guillo R, Battino M: Exogenous CoQ₁₀ supplementation prevents plasma ubiquinone reduction induced by the HMG CoA reductase inhibitors. *Mol Aspect Med* 15(S):187–193, 1994.
66. Folkers K, Osterborg A, Nylander M, Morita M, Melistedt H: Activities of vitamin Q in animal models and a serious deficiency in patients with cancer. *Biochem Biophys Res Commun* 234:296–299, 1997.
67. Gvozdjakova A, Kucharska J, Brannova Z, Kolesar P: Beneficial effect of CoQ₁₀ on the antioxidative status and metabolism of fats and sugars in diabetic patients. *Proc First Conference Internat Coenzyme Q₁₀ Assoc*, pp. 95–97, 1998.
68. Lester R, Crane FL: The natural occurrence of coenzyme Q and related compounds. *J Biol Chem* 234:2169–2175, 1959.
69. Weber C, Bysted A, Holmer G: Coenzyme Q₁₀ in the diet. Daily intake and relative bioavailability. *Mol Asp Med* 18 (S):251–254, 1997.
70. Spector DB, Seltzer WK, Goodman SI: Assignment of electron transfer flavoprotein-ubiquinone oxidoreductase (ETFQO) to human chromosome 4q33. *Mol Genet Metabol* 67:364–367, 1999.
71. McCady MF: Can correction of sub-optimal coenzyme Q status improve beta-cell function in type II diabetics? *Med Hypotheses* 52:397–400, 1999.
72. Santos-Ocaña C, Villalba JM, Cordoba F, Padilia S, Crane FL, Clarke CF, Navas P: Genetic evidence for coenzyme Q in plasma membrane electron transport. *J Bioenerg Biomemb* 30:465–472, 1998.
73. Crane FL, Löw H: New functions for coenzyme Q. In Ebadi M, Marwak J, Chopra RK (eds): "Mitochondrial Ubiquinone (Coenzyme Q)," vol. 1. Scottsdale: Prominent Press, pp 183–216, 2001.
74. Rustin P, Munnich A, Rötig A: Quinone analogs prevent enzymes targeted in Friedreich ataxia from iron induced injury in vitro. *Biofactors*: 247–251, 1999.
75. Sun IL, Nayas P, Crane FL, Morré DJ, Löw H: NADH diferric transferrin reductase activity in liver plasma membranes. *J Biol Chem* 262:15915–15921, 1987.
76. Löw H, Crane FL, Partick EJ, Clark MG: α adrenergic stimulation of transsarcolemma electron efflux in perfused rat heart. Possible regulation of Ca⁺⁺ channels by a sarcolemma redox system. *Biochem Biophys Acta* 844:142–148, 1985.
77. Löw PS, Kiyatkin A, Li Q, Harrison ML: Control of erythrocyte metabolism by redox regulation of tyrosine phosphatases and kinases. *Protoplasma* 184:196–202.
78. Gonzalez-Reyes JA, Cordoba F, Navas P: Involvement of plasma membrane redox systems in growth control of animal and plant cells. In Asard H, Berczi A, Canbergs RJ (eds): "Plasma Membrane Redox Systems and their Role in Biological Stress and Disease." Dordrecht: Kluwer, pp 193–213, 1998.
79. Smith A: Links between cell surface events involving redox active copper and gene regulation in the hemopexin heme transport system. *Antioxid Redox Signal* 2:157–175, 2000.
80. Garner B, van Reyk D, Dean R, Jessup W: Direct copper reduction by macrophages. *J Biol Chem* 272:6927–6935, 1997.

Received October 10, 2000; revision accepted April 20, 2001.